BioMedNewsBreaks – InvestorBrandNetwork, BioMedWire to Collaborate with Q1 Productions for Slate of Upcoming Events

InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, today announced that it will collaborate with Q1 Productions as an official media sponsor for its full event lineup in 2021. IBN also announced that BioMedWire (“BMW”), a specialized communications platform for the life sciences sector and one of the 50+ brands part of the InvestorBrandNetwork, will also be joining as an official media sponsor for Q1 Productions’ upcoming events. Over the past 15 years, Q1 Productions has established a strong reputation specializing in providing high-level educational content through a myriad of conferences, forums, webinars and other services. “We are delighted to be collaborating with InvestorBrandNetwork and BioMedWire,” said Paul Northover, CEO at Q1 Productions. “IBN’s widespread syndication network and direct reach in the life sciences industry delivers incredible exposure. Moreover, their multifaceted approach, which incorporates access to millions of followers across a range of social media platforms, helps complement our existing strategy to reach larger audiences.”

To view the full press release, visit https://ibn.fm/kPNj2

About InvestorBrandNetwork

The InvestorBrandNetwork (“IBN”) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through BioMedWire (“BMW”) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.

For more information on IBN, visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN wherever published or re-published: https://IBN.fm/Disclaimer

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Submits IND Amendment for Planned Phase 2a Trial of TTX-MC138 in Colorectal Cancer

TransCode Therapeutics (NASDAQ: RNAZ) announced the submission of an Investigational New Drug ("IND") application amendment…

1 day ago

BioMedNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports New Cellular Data Demonstrating Coordinated Intracellular Zinc Increase and Iron Reduction With Telomir-Zn

Telomir Pharmaceuticals (NASDAQ: TELO) announced new cellular study results showing that Telomir-1, administered as Telomir-Zn,…

1 day ago

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Engages DUCK FLATS Pharma for IND Readiness and Regulatory Execution

Oragenics (NYSE American: OGEN) announced that it has engaged DUCK FLATS Pharma as its U.S.…

3 days ago

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Participates in SCOPE Summit 2026 Ahead of Phase 2a Concussion Trial

Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company developing intranasal therapeutics for neurological disorders, announced…

4 days ago

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Mission Matters Podcast Interview With President Anil Diwan

NanoViricides, Inc. (NYSE American: NNVC) announced that President Dr. Anil R. Diwan was interviewed on…

4 days ago

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q®…

7 days ago